Physician profile
Jason K Boyd
NPI 1316986425
$4,460.70
in general payments reported to CMS, 2019-2025
60 companies · $1,992 in 2025
The $1,992 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $83.90 · 2021: $206 · 2022: $431 · 2023: $707 · 2024: $878 · 2025: $1,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $38.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.16 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $38.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,371.10 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $263.41 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $241.88 | 2022-2025 | Tecvayli, Darzalex, Erleada |
| Pfizer INC. | $155.61 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.14 | 2023-2025 | Ninlaro, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $125.11 | 2022-2025 | Calquence, Enhertu, Lynparza |
| Incyte Corporation | $123.59 | 2021-2022 | |
| Genmab U.S., INC. | $118.87 | 2023-2025 | Epkinly, Tivdak |
| Genzyme Corporation | $110.31 | 2019-2024 | |
| Daiichi Sankyo INC. | $96.16 | 2021-2024 | Enhertu, Injectafer |
| Eisai INC. | $92.57 | 2022-2025 | |
| Celgene Corporation | $83.96 | 2023-2024 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $82.67 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $74.29 | 2023 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $72.32 | 2024-2025 | Libtayo, Lynozyfic |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $66.28 | 2023-2025 | |
| Exelixis INC. | $50.49 | 2019-2025 | Cabometyx |
| Taiho Oncology, INC. | $49.40 | 2025 | |
| Sobi, INC | $46.34 | 2022-2024 | |
| Stemline Therapeutics INC. | $44.34 | 2023-2025 | Orserdu, Elzonris |
| Genentech USA, INC. | $42.12 | 2022-2024 | Tecentriq, Alecensa, Venclexta |
| G1 Therapeutics, INC. | $41.75 | 2022-2023 | Cosela |
| Geron Corporation | $39.55 | 2025 | Rytelo |
| Abbvie INC. | $39.50 | 2023-2025 | Venclexta |
| Karyopharm Therapeutics INC. | $39.21 | 2023 | Xpovio |
| Asd Specialty Healthcare, LLC | $38.95 | 2021 | |
| Foundation Medicine, INC. | $38.73 | 2020 | |
| Gilead Sciences, INC. | $38.25 | 2021-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $38.11 | 2023-2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $38.09 | 2019-2024 | Opdivo |
| Aveo Pharmaceuticals, INC. | $37.42 | 2022-2025 | |
| Array Biopharma INC | $35.83 | 2020-2025 | Mektovi, Tukysa, Braftovi |
| Adc Therapeutics America, INC. | $32.98 | 2023 | |
| Beone Medicines USA, INC. | $31.55 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $30.78 | 2022-2023 | Beleodaq |
| Astellas Pharma US INC | $29.94 | 2023-2025 | Vyloy, Xospata |
| Tersera Therapeutics LLC | $25.37 | 2025 | Xermelo |
| Seagen INC. | $24.58 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Epizyme, INC. | $23.76 | 2021 | |
| Servier Pharmaceuticals LLC | $23.45 | 2024 | |
| Dendreon Pharmaceuticals LLC | $22.14 | 2024 | Provenge |
| Recordati_rare_diseases_inc. | $21.93 | 2024 | Sylvant |
| Coherus Oncology, INC. | $21.71 | 2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $21.11 | 2025 | Monoferric |
| Nuvation Bio INC. | $21.09 | 2025 | Ibtrozi |
| Organon LLC | $20.48 | 2022 | |
| Lilly USA, LLC | $20.23 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.77 | 2023 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $19.70 | 2025 | |
| Rigel Pharmaceuticals, INC. | $18.92 | 2024 | Tavalisse, Rezlidhia |
| Secura Bio, INC. | $17.32 | 2019 | |
| Glaxosmithkline, LLC. | $16.84 | 2024 | Jemperli, Zejula |
| Morphosys, US INC. | $15.61 | 2024 | Monjuvi |
| Beigene USA, INC. | $15.39 | 2024 | Brukinsa |
| Celltrion USA INC. | $15.25 | 2024 | Vegzelma |
| Fennec Pharmaceuticals, INC. | $14.56 | 2025 | Fyarro |
| Puma Biotechnology, INC. | $13.91 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $13.70 | 2025 | Sancuso |
| Pharmacyclics LLC, An Abbvie Company | $13.35 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.